Skip to main content
TipRanks
Go Ultimate75% OFF

SIGA Technologies (SIGA) AI Stock Analysis

495 Followers
SIGA

SIGA Technologies

(NASDAQ:SIGA)

Select Model
Rating:49Neutral
Price Target:$2.50â–¼(-8.76% Downside)
Action:reiterated
Date:11/10/26

The overall score is weighed down by a severe deterioration in current financial performance and a weak technical trend. The company is currently unprofitable and burning cash, with the stock in a clear downtrend. The primary support comes from a pristine, debt-free balance sheet and a moderately positive long-term outlook from the earnings call, driven by international contract wins and a strong cash position. However, the near-term uncertainty around U.S. procurement and delayed pipeline milestones presents significant risk.

Positive Factors
Strong balance sheetA cash-rich, debt-free balance sheet gives SIGA meaningful financial flexibility while it navigates uneven procurement timing and funds ongoing development. This reduces solvency pressure, supports continued operations, and preserves the capacity to invest in formulations and regulatory programs.
Negative Factors
Recent cash-flow deteriorationThe shift from historically strong cash generation to negative trailing-twelve-month operating and free cash flow weakens near-term earnings quality. If sustained, it could reduce self-funding capacity and make results more dependent on the timing of government deliveries.

SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%SIGA-47.59%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$196.88M
Dividend Yield
―
Average Volume (3M)
625.45K
Price to Earnings (P/E)
428.1
Beta (1Y)
1.20
Revenue Growth
-69.60%
EPS Growth
-99.10%
Country
US
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

SIGA Technologies Business Overview & Revenue Model

Company Description

SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human...

How the Company Makes Money

SIGA makes money primarily by selling TPOXX (tecovirimat) under government procurement and stockpiling programs for biodefense and emergency preparedness. A significant portion of revenue is generated through contracts and purchase orders from govern...

SIGA Technologies Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-15.95%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was generally positive, supported by completion of the BARDA 19C contract, a new Canadian agreement worth up to approximately $15 million, additional international discussions, broad TPOXX approvals and stockpiling, nine-month profitability, and a cash balance of approximately $116 million with no debt. Offsetting concerns included uncertain timing for a new U.S. procurement award, the PEP filing delay to 2028, no third-quarter product sales, third-quarter losses, and timing challenges in Europe.

Positive Updates

BARDA 19C Contract Fully Completed
SIGA completed its final product delivery under the BARDA 19C contract in the second quarter, fulfilling all product obligations and contributing to U.S. government smallpox preparedness.

Negative Updates

Uncertain Timing for New U.S. Procurement
The process to secure a new U.S. government contract has progressed more slowly than in the past, and the timing of an award remains uncertain. Management said it continues to believe a new procurement contract will be awarded, but acknowledged uncertainty regarding timing and details.

Company Guidance

SIGA expects results from the phase I study of its pediatric formulation by year end, and expects to file its supplemental NDA for the PEP program in 2028. Under the CDND contract, valued up to approximately $15 million over the next five years, firm commitments are about $9 million over the first three years, plus up to $6 million in options; deliveries are expected to start in 2027, with an equal number of oral TPOXX courses delivered in each of the first three fiscal years, while options can be ordered and delivered at any point in time during the five-year contract. SIGA continues to believe that a new U.S. procurement contract will be awarded, although the timing of an award remains uncertain, and does not currently expect the midterm results to have any material impact on the nature or trajectory of the process beyond the typical transition period that follows any election.

SIGA Technologies Financial Statement Overview

Summary

Financial performance is deeply bifurcated. The balance sheet is a fortress with zero debt and substantial cash, but the income statement and cash flow statement show a business in steep decline, with severe margin compression, net losses, and negative free cash flow in the TTM period. The overall score reflects a rock-solid foundation being actively eroded by an unprofitable operating model.

Income Statement

25Negative

Balance Sheet

85Very Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue52.36M94.60M138.72M139.92M110.78M133.67M
Gross Profit28.29M64.87M107.43M122.09M100.34M117.07M
EBITDA-2.17M30.96M76.61M88.31M44.65M89.83M
Net Income716.12K23.30M59.21M68.07M33.90M69.45M
Balance Sheet
Total Assets172.65M219.47M244.34M254.35M195.04M214.73M
Cash, Cash Equivalents and Short-Term Investments116.38M154.97M155.40M150.15M98.79M103.14M
Total Debt274.61K595.17K546.82K564.01K528.17K466.83K
Total Liabilities9.39M20.65M28.53M57.49M24.88M40.41M
Stockholders Equity163.25M198.82M215.80M196.86M170.16M174.31M
Cash Flow
Free Cash Flow-11.57M43.12M48.72M94.78M41.61M11.44M
Operating Cash Flow-11.53M43.47M48.76M94.80M41.61M11.49M
Investing Cash Flow-40.54K-355.01K-42.45K-21.69K0-50.62K
Financing Cash Flow-44.00M-43.55M-43.46M-43.42M-45.96M-26.20M

SIGA Technologies Technical Analysis

Technical Analysis SentimentNegative
Last Price2.74

Price Trends

50DMA3.17Negative
100DMA3.23Negative
200DMA4.04Negative

Market Momentum

MACD-0.06Positive
RSI36.11Neutral
STOCH15.74Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 2.74 is below the 20-day moving average (MA) of 3.10, below the 50-day MA of 3.17, and below the 200-day MA of 4.04, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 15.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.

SIGA Technologies Risk Analysis

SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Affiliates of MacAndrews & Forbes Incorporated (together with its affiliates "MacAndrews") have substantial ownership of SIGA stock and their interests may differ from the interests of other stockholders.Q4, 2025
2.Failure to maintain existing regulatory approvals or obtain future regulatory approvals in additional international jurisdictions could prevent us from marketing our products in certain jurisdictions abroad.Q2, 2025
3.We recently reacquired international promotional rights and we may be unable successfully to expand our internal international sales and marketing capabilities or enter into agreements with third parties outside of the U.S..Q4, 2024

SIGA Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SIGA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RDYRDY68Neutral$12.18B41.077.37%0.57%-10.52%-55.45%
VTRSVTRS58Neutral$23.87B-39.28-4.24%2.31%4.80%82.97%
CPHICPHI56Neutral$22.29M-0.51-17.14%―-10.97%71.83%
PRGOPRGO52Neutral$2.25B-1.27-68.13%7.14%-4.45%-3289.03%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SIGASIGA49Neutral$196.88M428.120.42%―-69.60%-99.10%
EBSEBS45Neutral$297.69M-1.15-61.33%―-17.72%-456.60%

* Healthcare Sector Average

Performance Comparison

0%200%400%SIGACPHIRDYEBSVTRSPRGODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SIGA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SIGASiga Technologies2.74-2.54-48.12%
CPHIChina Pharma0.52-1.00-65.92%
RDYDr. Reddy's Laboratories Ltd14.740.805.72%
EBSEmergent Biosolutions5.79-4.33-42.79%
VTRSViatris, Inc.20.8210.48101.30%
PRGOPerrigo Company16.244.0032.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026